1. Medtech Insight
  2. >>Archive

InfraReDx’s Long Road To Commercialization Continues With Latest Financing

InfraReDx raised $25 million in late August, another step in its long journey to change the standard of care for coronary artery disease. With the latest financing, the company has raised some $175 million since its founding in 1998, and although it still has far to go, in that length of time InfraReDx, and an understanding of coronary artery disease, have come a long way.

Through good and bad financing climates, InfraReDx Inc., a pioneer in improving the understanding of the vascular lesions that cause coronary artery disease, continues to attract investors’ interest. In late August, the company raised another $25 million, increasing its total funding to some $175 million since its founding in 1998. [See Deal][See Deal][See Deal] Even at that level of investment, the firm, by its own admission, still has a long way to go on its long journey to change the standard of care for coronary artery disease.

With that said, there is no doubt that InfraReDx has made important progress in this complex area, and investors continue to have confidence in the company’s approach. Company founder James Muller, MD, a cardiologist and winner of the Nobel Peace Prize, was one of first to coin the phrase “vulnerable plaque” back in 1989, giving form to the idea that there is a certain kind of lipid-rich plaque that can cause heart attacks, even in the absence of significant stenosis, by rupturing and creating a thrombus that blocks the artery

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

FDA Announces Classifications On 8 Device Types

 
• By Elizabeth Orr

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

State And International Enforcement Agencies May Step Up Amid Uncertain Federal Environment

 
• By Elizabeth Orr

States and international regulatory bodies may increase their US enforcement role following federal staff cuts, Hyman Phelps & McNamara attorneys said in a recent webinar. The attorneys also expect False Claims Act enforcement and public health to remain key areas of focus at the federal level.